BioCentury | May 12, 2014
Emerging Company Profile

Pharmasum: Down with AD

Pharmasum Therapeutics A/S is looking to treat the large number of Down syndrome patients who develop Alzheimer's disease-like pathology. The company's first-in-class inhibitor could slow cognitive decline in Down syndrome by targeting a kinase that...
BC Week In Review | Jan 21, 2013
Clinical News

Proteome Sciences preclinical data

In a mouse model of AD, PS110 improved cognitive function as assessed by the Morris Water Maze test vs. vehicle-treated controls. Proteome said next steps include pharmacokinetic testing of the casein kinase 1 delta ( CSNK1D...
BC Week In Review | Jan 21, 2013
Clinical News

Proteome Sciences preclinical data

In a mouse model of AD, PS278-05 improved cognitive function as assessed by the Morris Water Maze test vs. vehicle-treated controls. Proteome said next steps include pharmacokinetic testing of the casein kinase 1 delta ( CSNK1D...
BC Innovations | Oct 20, 2011
Distillery Therapeutics

Indication: Various

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Insomnia; diabetes; cardiovascular disease Casein kinase 1d (CSNK1D; CKI-d) A small molecule inhibitor of CKI-d that prolongs circadian rhythms could help...
BC Week In Review | Aug 30, 2010
Clinical News

Pfizer preclinical data

Researchers at the University of Manchester and colleagues reported that once-daily PF-670462 produced "robust" 24-hour activity cycles that persisted throughout treatment in mice rendered behaviorally arrhythmic. PF-670462 is a casein kinase 1 delta ( CSNK1D ;...
Items per page:
1 - 5 of 5